Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TUBB4A | P04350 | 5/20 | 0.44 |
| ▸ | TUBB | P07437 | 5/20 | 0.44 |
| ▸ | TUBA3C | P0DPH7 | 5/20 | 0.44 |
| ▸ | TUBA1B | P68363 | 5/20 | 0.44 |
| ▸ | TUBA4A | P68366 | 5/20 | 0.44 |
| ▸ | TUBB4B | P68371 | 5/20 | 0.44 |
| ▸ | TUBB3 | Q13509 | 5/20 | 0.44 |
| ▸ | TUBB2A | Q13885 | 5/20 | 0.44 |
| ▸ | TUBB8 | Q3ZCM7 | 5/20 | 0.44 |
| ▸ | TUBA3E | Q6PEY2 | 5/20 | 0.44 |
| ▸ | TUBA1A | Q71U36 | 5/20 | 0.44 |
| ▸ | TUBA1C | Q9BQE3 | 5/20 | 0.44 |
| ▸ | TUBB6 | Q9BUF5 | 5/20 | 0.44 |
| ▸ | TUBB2B | Q9BVA1 | 5/20 | 0.44 |
| ▸ | TUBB1 | Q9H4B7 | 5/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (-)-Steganacin SCHEMBL10065023 | 1.00 | LMNA (0.57) | LMNACYP3A4POLBHTTTUBB4A | |
| Steganacin SCHEMBL14138211 | 1.00 | LMNA (0.57) | LMNACYP3A4POLBHTTTUBB4A | |
| SCHEMBL19050768 | 0.91 | CYP3A4 (0.53) | LMNACYP3A4POLBHTTTUBB4A | |
| Steganacin SCHEMBL8044045 | 0.89 | CYP3A4 (0.48) | LMNACYP3A4POLBHTTTUBB4A | |
| SCHEMBL5014622 | 0.86 | CYP3A4 (0.54) | LMNACYP3A4POLBTUBB4ATUBB | |
| SCHEMBL14097830 | 0.86 | CYP3A4 (0.54) | LMNACYP3A4POLBTUBB4ATUBB | |
| SCHEMBL9951919 | 0.77 | GSK3B (0.47) | LMNACYP3A4POLBTUBB4ATUBB | |
| Stegane SCHEMBL5014561 | 0.76 | TUBB4A (0.53) | POLBTUBB4ATUBBTUBA3CTUBA1B | |
| Picrostegane SCHEMBL14097820 | 0.76 | TUBB4A (0.53) | POLBTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL4276054 | 0.73 | LMNA (1.00) | LMNACYP3A4HTTTUBB4ATUBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 603 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4479042-A1 | CANCER TREATMENT BY COMBINED INHIBITION OF POLO-LIKE KINASE AND MICROTUBULE POLYMERIZATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-12-25 | — | — | EP | claimed |
| WO-2023158514-A1 | CANCER TREATMENT BY COMBINED INHIBITION OF POLO-LIKE KINASE AND MICROTUBULE POLYMERIZATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-08-24 | — | — | WO | claimed |
| US-20230263783-A1 | CANCER TREATMENT BY COMBINED INHIBITION OF POLO-LIKE KINASE AND MICROTUBULE POLYMERIZATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2023-08-24 | — | — | US | claimed |
| WO-2020127946-A2 | TUBULIN INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF METASTASIS | UNIVERSITÄT BASEL (CH) | 2020-06-25 | — | — | WO | claimed |
| CN-110248680-A | Therapy for metastatic urothelial cancer using antibody-drug conjugate sabitumumab gavitikang (IMMU-132) | 免疫医疗公司 | 2019-09-17 | — | — | CN | claimed |
| CN-108289900-A | Use of tocotrienol derivatives | 北京蔚蓝之源医药科技有限公司 | 2018-07-17 | — | — | CN | claimed |
| CN-106668031-A | Application of tocotrienol derivative | 北京蔚蓝之源医药科技有限公司 | 2017-05-17 | — | — | CN | claimed |
| EP-2356462-B1 | ANTI-CXCR1 COMPOSITIONS AND METHODS | UNIV MICHIGAN REGENTS (US) | 2017-01-04 | — | — | EP | claimed |
| US-9358303-B2 | Compounds containing a vascular disrupting agent | INCANTHERA LTD (GB) | 2016-06-07 | — | — | US | claimed |
| EP-2481428-B1 | MMP activated vascular disrupting agents | INCANTHERA LTD (GB) | 2016-03-02 | — | — | EP | claimed |
| WO-2007054551-A1 | COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-18 | — | — | WO | claimed |
| WO-2007009201-A2 | PROCESS TO OBTAIN SYNTHETIC AND SEMI-SYNTHETIC LIGNAN DERIVATIVES, THEIR ANTIPARASITIC ACTIVITIES AND CORRESPONDING PHARMACEUTICAL FORMULATIONS, INCLUDING THE THERAPEUTIC METHOD USING SAID LIGNAN FOR THE TREATMENT OF PARASITOSIS | Fundação De Amparo À Pesquisa Do Estado de São Paulo (BR) | 2007-01-25 | — | — | WO | claimed |
| JP-2006524634-A | — | — | 2006-11-02 | — | — | JP | claimed |
| US-20060058311-A1 | Combinations for the treatment of diseases involving cell proliferation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-03-16 | — | — | US | claimed |
| WO-2006018182-A1 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-23 | — | — | WO | claimed |
| EP-1622619-A2 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS | Boehringer Ingelheim International GmbH (DE) | 2006-02-08 | — | — | EP | claimed |
| US-20050043233-A1 | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-24 | — | — | US | claimed |
| WO-2004096224-A2 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-11-11 | — | — | WO | claimed |
| CN-1543356-A | Antitumor agent | ֮����ʽ���� | 2004-11-03 | — | — | CN | claimed |
| WO-2000035865-A2 | TUBULIN-BINDING AGENTS | TULARIK INC. (US) | 2000-06-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230263783-A1 | CANCER TREATMENT BY COMBINED INHIBITION OF POLO-LIKE KINASE AND MICROTUBULE POLYMERIZATION | PLK2, PLK4, PLK1 | LMNA 1081/4885CYP3A4 4536/4885POLB 199/4885 |
| US-20060058311-A1 | Combinations for the treatment of diseases involving cell proliferation | CCNA1, MKI67, CCNA2 | LMNA 1168/4885CYP3A4 3900/4885POLB 663/4885 |
| US-20050043233-A1 | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis | BAX, BCL2, CXCL12 | LMNA 1029/4885CYP3A4 4516/4885POLB 2772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.